About dNovo
dNovo is a Healthcare company based in San Francisco (United States) founded in 2018. It operates in the Healthcare and Business Services sectors. dNovo has raised $2.7 million across 1 funding round from investors including Yintai, Soma Capital and Felicis Ventures. Its chief executive, as recorded, is Ernesto Lujan. Its focus areas include Consumer, Professional Consumer Services, Life Sciences and Dermatology. Its competitors include Stemson Therapeutics and Pelage Pharmaceuticals; 2 of its 2 listed competitors have raised funding.
Company details
Developer of a hair loss treatment using reprogrammed stem cells. This treatment addresses the root cause of hair loss by generating new, personalized hair stem cells from a patients own skin or blood. The companys proprietary technology involves reprogramming these cells to replace lost or damaged hair stem cells, resulting in new hair growth. The process involves collecting cells, adding reprogramming factors, generating hair-producing cells, seeding them onto the scalp, and observing hair growth within months. The technology has shown promising results in pre-clinical trials.
- Headquarters San Francisco, United States
- SectorsHealthcareBusiness Services
- Website dnovobio.com
- Total Equity Funding$2.7M (USD)
in 1 rounds
- Latest Funding Round$2.7M (USD), Seed
Jan 2022
- InvestorsYintai
& 15 more
Funding Insights of dNovo
dNovo has successfully raised a total of $2.7M through 1 strategic funding round. The most recent funding activity was a Seed round of $2.7 million completed in January 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $2.7M
- Total Rounds 1
- Last Round Seed — $2.7M
- First Round $2.7M
(Jan 2022)
- Investors Count 16
All 1 funding rounds of dNovo with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2022 | $2.7M | Seed | – | – |
16 investors in total: 7 institutional and 9 angel.
Investors in dNovo
dNovo has secured backing from 16 investors, including venture fund and angel investors. Prominent investors backing the company include Yintai, Soma Capital and Felicis Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| yintai-us.com | ||||
Early-stage investments are provided by Soma Capital to startups. | somacap.com | San Francisco, United States | ||
Investments in technology startups are made by Felicis Ventures. | felicis.com | Menlo Park, United States | ||
Early-stage startups are accelerated via funding and educational programs. | ycombinator.com | Mountain View, United States | ||
Venture capital firm focused on early-stage startups | atariaventures.com | San Isidro, Peru | ||
Investments in multiple sectors are made by Pioneer Fund. | pioneerfund.vc | San Francisco, United States | ||
Venture capital firm investing in multiple sectors | duro.vc | San Francisco, United States | ||
PB Paul Buchheit | Creator of Gmail, angel investor, and Y Combinator partner | unknown_e8b14042759949339 | ||
MK Max Kolysh | unknown_ade4c9f8f6da4f18b | |||
JH Jason Hodges | unknown_9ad5986e8a5142d78 |
Investor details for dNovo
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of dNovo
1 people are tracked at dNovo (1 in leadership).
| Name | Role | Group |
|---|---|---|
Ernesto Lujan | CEO | Leadership |
Complete people profiles for dNovo
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of dNovo
2 dated milestones of dNovo across 4 years, from founding to its latest funding, stage changes and deals.
- Founded dNovo is founded.
- Funding First funding round of $2.7M.
Competitors of dNovo
dNovo has 2 listed competitors in our database, 2 of them funded. They include Stemson Therapeutics and Pelage Pharmaceuticals.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| stemsontx.com | 2019 | San Diego, United States | $22.5M | Stem cell-based therapy for hair growth is developed using iPSCs. | ||
| pelagepharma.com | 2018 | Los Angeles, United States | $150.8M | Developer of therapeutics for hair loss treatment in men and women |
Detailed competitors of dNovo
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Dermatology
3 companies that operate in the same segment as dNovo (Dermatology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Neurotoxin products for aesthetic and therapeutic skin treatments are developed. | 2002 | Newark, New Jersey, United States | USD 154.56 M | USD 234.04 M | 597 | |
Diagnostic tests for cancer prognosis are provided. | 2008 | Friendswood, Texas, United States | USD 61.97 M | USD 344.23 M | 761 | |
Adhesive patch biopsies for skin cancer detection are provided. | 1996 | San Diego, California, United States | USD 24.37 M | USD 15.3 M | 259 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about dNovo
dNovo was founded in 2018 and raised its 1st funding round 4 years after it was founded.
dNovo is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Ernesto Lujan is the CEO of dNovo, as recorded in our data.
dNovo is a funded company, having raised a total of $2.7M across 1 funding round to date. The company's 1st funding round was a Seed of $2.7M, raised on Jan 2022.
Developer of a hair loss treatment using reprogrammed stem cells. This treatment addresses the root cause of hair loss by generating new, personalized hair stem cells from a patients own skin or blood. The companys proprietary technology involves reprogramming these cells to replace lost or damaged hair stem cells, resulting in new hair growth. The process involves collecting cells, adding reprogramming factors, generating hair-producing cells, seeding them onto the scalp, and observing hair growth within months. The technology has shown promising results in pre-clinical trials.
dNovo's top competitors include Pelage Pharmaceuticals and Stemson Therapeutics.
dNovo has 16 investors. Key investors include Yintai, Soma Capital, Felicis Ventures, Y Combinator, and Ataria Ventures.